6IV.F INVENTIVA S.A.(PROM.)-01
- Market cap
- EUR 779M
- P/E
- -
- P/B
- 13.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6IV.F undervalued?
Graham numberThe Graham number of INVENTIVA S.A.(PROM.)-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INVENTIVA S.A.(PROM.)-01 fundamental analysis
No fundamental analysis for INVENTIVA S.A.(PROM.)-01 yet.
INVENTIVA S.A.(PROM.)-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INVENTIVA S.A.(PROM.)-01
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharido…
Full company profileINVENTIVA S.A.(PROM.)-01 financial statements
INVENTIVA S.A.(PROM.)-01 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 4.19M | 12.2M | 17.5M | 9.20M | 4.48M |
| Operating Income | -51.2M | -56.9M | -103M | -94.0M | -133M |
| EBITDA | - | -51.9M | -102M | -167M | -317M |
| Net Income | -49.6M | -54.3M | -110M | -184M | -354M |
| EPS | -1.21 | -1.29 | -2.12 | -1.93 | -1.85 |
| Balance Sheet | |||||
| Total Assets | 122M | 116M | 69.6M | 119M | 250M |
| Total Liabilities | 33.1M | 70.5M | 102M | 226M | 278M |
| Shareholders' Equity | 88.9M | 45.5M | -32.0M | -107M | -28.5M |
| Cash & Short-term Investments | 86.6M | 86.7M | 26.9M | 96.6M | 99.3M |
| Cash Flow | |||||
| Operating Cash Flow | -47.6M | -44.9M | -81.6M | -85.9M | -105M |
| Capital Expenditure | 534K | 561K | 540K | 333K | 247K |
| Free Cash Flow | -48.2M | -45.5M | -82.2M | -86.3M | -105M |
| Ratios | |||||
| ROE | -55.9% | -119.3% | - | - | - |
| ROA | -40.7% | -46.8% | -158.7% | -154.8% | -141.9% |
| Net Profit Margin | -1,183.5% | -445.6% | -631.8% | -2,002.7% | -7,899.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INVENTIVA S.A.(PROM.)-01 dividends
INVENTIVA S.A.(PROM.)-01 has not paid dividends in the last 5 fiscal years.
Who owns INVENTIVA S.A.(PROM.)-01
- Insiders 12.52%
- Institutions 49.41%
- Public & others 38.07%
- Shares outstanding 239M
- Free float 180M
INVENTIVA S.A.(PROM.)-01 company profile
- Company name
- INVENTIVA S.A.(PROM.)-01
- Ticker
- 6IV.F
- ISIN
- FR0013233012
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 50 rue de Dijon, Daix, France, 21121
- Phone
- 33 3 80 44 75 00
- Website
- inventivapharma.com
About INVENTIVA S.A.(PROM.)-01
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
INVENTIVA S.A.(PROM.)-01 management
10- Mr. Andrew ObenshainChief Executive Officer · born 1974
- Dr. Pierre Broqua Ph.D.Co-Founder · born 1962
- Mr. Jean VolatierExecutive VP Finance & Corporate Social Responsibility · born 1965
- Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs · born 1969
- Mr. Jason A. Campagna M.D., Ph.D.President of Research & Development and Chief Medical Officer · born 1966
- Mr. Axel-Sven MalkomesChief Financial Officer · born 1967
- Mr. Christopher Benecchi M.B.A.Chief Operating Officer · born 1972
- Ms. Jennifer NavaChief Information Officer
- Ms. Susan ColesChief Legal Officer · born 1966
- Ms. Pamela HerbsterChief People Officer